Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States

ObjectiveNivolumab, recently proven in a phase 3 clinical trial (CheckMate 901) to enhance survival when combined with gemcitabine-cisplatin for advanced urothelial carcinoma. This study aimed to assess its cost-effectiveness against gemcitabine-cisplatin alone, from US and Chinese payers’ perspecti...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Guiyuan Xiang, Yueyue Huang, Lanlan Gan, Linning Wang, Yunqi Ding, Yuanlin Wu, Haiyan Xing, Yao Liu
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2024-09-01
Ráidu:	Frontiers in Immunology
Fáttát:	nivolumab urothelial carcinoma cost-effectiveness gemcitabine cisplatin chemotherapy
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1426024/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!